Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group
A. C. Carter, N. Sedransk, R. M. Kelley, F. J. Ansfield, R. G. Ravdin, R. W. Talley and N. R. Potter
A total of 523 postmenopausal breast cancer patients with progressive
disease were entered in a radomized, double-blind study of four dosages of
diethylstibestrol (DES): 1.5, 15, 150, OR 1,500 MG/DAY. Higher dosages
produced significantly (p less than .05) higher regression rates: 21% for
the 1,500 mg dosage, 17% for the 150 mg dosage, 15% for the 15 mg dosage,
and 10% for 1.5 mg dosage. Durations of regressions were similar regardless
of the dosages used to induce them. Although the highest dosage produced
the highest regression rate overall, selecting the best dosage or treatment
of choice for each type of patient based on menopausal age and on dominant
metastatic site would result in more regressions.
